<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="28726">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02732769</url>
  </required_header>
  <id_info>
    <org_study_id>2015-40</org_study_id>
    <secondary_id>2015-A01673-46</secondary_id>
    <nct_id>NCT02732769</nct_id>
  </id_info>
  <brief_title>Clinical Evaluation of the Treatment of Intellectual Metastases by Radiosurgery Gamma Knife by Means of a Support System by Mask.</brief_title>
  <acronym>Mask</acronym>
  <official_title>Clinical Evaluation of the Treatment of Intellectual Metastases by Radiosurgery Gamma Knife by Means of a Support System by Mask.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique Hopitaux De Marseille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique Hopitaux De Marseille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      the Mask fixation isn't a new solution for the immobilization of the patient's head and has
      been used in current practice for long years.

      This trial is attempting to compare these two technical possibilities of head fixation by
      mask or by stereotaxic frame. The primary goal is to evaluate the comfort for the patient
      and specifically for each step of the procedure. It will also evaluate other parameters such
      as the effectiveness of these two strategies and tolerance.The expected benefit is an
      improvement of the comfort for the patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">February 2017</completion_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of digital scale of pain</measure>
    <time_frame>12 months</time_frame>
    <description>Questionary (EN)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of tumor control</measure>
    <time_frame>12 months</time_frame>
    <description>No increase of volume greater than 50% on the MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of clinical side effects</measure>
    <time_frame>12 months</time_frame>
    <description>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">58</enrollment>
  <condition>Lung Cancer</condition>
  <condition>Brain Metastases</condition>
  <arm_group>
    <arm_group_label>Group treated by radiosurgery</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will receive a pituitary radiosurgery during a brief hospitalization by LeksellGammaKnifePerfexion® (LGKP)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group treated by radiosurgery with the thermoformed mask</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a pituitary radiosurgery with thermoformed mask during a brief hospitalization by GammaKnifeICON® (GKI) with Efficast®</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>GammaKnifePerfexion®</intervention_name>
    <description>neurosurgery</description>
    <arm_group_label>Group treated by radiosurgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>GammaKnifeIcon®</intervention_name>
    <description>neurosurgery</description>
    <arm_group_label>Group treated by radiosurgery with the thermoformed mask</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Efficast®</intervention_name>
    <description>Thermoformed mask</description>
    <arm_group_label>Group treated by radiosurgery with the thermoformed mask</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MRI</intervention_name>
    <arm_group_label>Group treated by radiosurgery</arm_group_label>
    <arm_group_label>Group treated by radiosurgery with the thermoformed mask</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject bearing of one to five intellectual metastases of lung origin at the time of
             the indication of the radiosurgery

          -  Subject requiring a radiosurgical treatment with LGK

        Exclusion Criteria:

          -  Subject having hurts of the brainstem or para-optics

          -  Pregnant women or in feeding period

          -  Subject having received previously a split conventional radiotherapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>DESALBRES</last_name>
    <role>Study Director</role>
    <affiliation>ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean REGIS</last_name>
    <email>jean.regis@ap-hm.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Assistance Publique Hôpitaux de Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>13354</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Urielle DESALBRES, Director</last_name>
      <phone>0491382747</phone>
      <email>drci@ap-hm.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <lastchanged_date>April 8, 2016</lastchanged_date>
  <firstreceived_date>March 30, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
